AMZN
Amazon.com, Inc.
AMZN's fundamentals are mixed: revenue grew 15%, but free cash flow turned negative. Its PE of 22x looks cheaper than it really is, because one-off gains boosted its recent earnings. Analysts expect strong earnings growth.
CANG
Cango Inc.
There isn't enough reported data to score CANG yet.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
CANG Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Strong |
CANG's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
CANG PE Valuation
CANG has no meaningful PE right now: it lost money over the past year.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over CANG on the outlook, with more favorable revenue expectations.
CANG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect CANG's losses to shrink, with revenue declining.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the stronger earnings trend. Trailing diluted EPS is up 75% for AMZN versus CANG down 49%.
CANG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | $0.97 | +$1.09 |
| Q4 2023 | -$0.12 | +$2.93 |
| Q4 2022 | -$3.05 | -$3.02 |
| Q3 2022 | -$1.17 | -133% |
| Q2 2022 | -$1.89 | -121% |
| Q1 2022 | $0.30 | -96% |
| Q4 2021 | -$0.03 | -100% |
| Q3 2021 | $3.54 | -26% |
CANG has returned to profit: it earned $0.97 per share over the past year, after losing money the year before.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
CANG has the stronger quarterly revenue trend. Revenue is up 12% for AMZN versus up 453% for CANG.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN's operating margin was 14% last quarter, up 4.2 points from the same quarter a year ago, near the top of its range since 2019.
CANG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $404.1M | +235% |
| Q4 2024 | $120.7M | -53% |
| Q4 2023 | $255.4M | +249% |
| Q4 2022 | $73.1M | -54% |
| Q3 2022 | $62.5M | -48% |
| Q2 2022 | $43.4M | -69% |
| Q1 2022 | $118.2M | -30% |
| Q4 2021 | $157.7M | -4.3% |
CANG's revenue has grown year over year for four quarters in a row: $404M last quarter, up 453% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -58% | -14 points |
| Q2 2025 | -72% | -26 points |
| Q4 2024 | 22% | +145 points |
| Q4 2023 | -4.3% | +20 points |
| Q4 2022 | -43% | -29 points |
| Q3 2022 | -46% | -41 points |
| Q2 2022 | -122% | -124 points |
| Q1 2022 | -24% | -38 points |
CANG's operating margin was −58% last quarter, down 14 points from the same quarter a year ago, near the bottom of its range since 2016.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
CANG has the stronger cash trend. Its trailing FCF is up 365% versus its history, compared with AMZN at down 619%.
CANG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$46.6M | -130% |
| Q4 2023 | $153.7M | +$153.7M |
| Q4 2022 | $0 | $0 |
| Q3 2022 | $0 | $0 |
| Q2 2022 | $0 | $0 |
| Q1 2022 | $0 | $0 |
| Q4 2021 | $0 | $0 |
| Q3 2021 | $0 | $0 |
CANG usually generates cash, though not every quarter: the latest was −$47M, but it generated $107M over the past year.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
CANG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -9.5% | -4.4M shares |
| 1 year | -23% | -12.4M shares |
| 3 years | -30% | -17.9M shares |
| 5 years | -17% | -8.4M shares |
| Available history | -17% | -8.4M shares |
CANG has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | $13.6M |
| Q4 2023 | $37M |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CANG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -4.4x | Net Cash |
| Q4 2021 | 3.1x | Elevated |
| Q3 2021 | 4.0x | Elevated |
| Q2 2021 | 2.3x | Moderate |
| Q1 2021 | 1.5x | Healthy |
| Q4 2020 | 3.4x | Elevated |
| Q3 2020 | 4.0x | High |
| Q2 2020 | 0.8x | Very low |
CANG has more cash than debt.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
CANG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.8 | Neutral |
| Stochastic | 9.7 | Oversold |
CANG's weekly RSI is 40 (neutral) and its Stochastic is 10 (oversold).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
CANG PE vs Consumer Cyclical Sector
| Metric | CANG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
CANG has no meaningful PE right now: it lost money over the past year.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over CANG on trend strength, trading above more of its moving averages.
CANG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.09 | 24% below |
| 20 week MA | $2.03 | 22% below |
| 50 week MA | $5.48 | 71% below |
| 100 week MA | $13.7 | 88% below |
| 200 week MA | $10.7 | 85% below |
CANG is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over CANG on returns for 2026, with the stronger performance.
CANG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $43.0 | $36.3 | -16% |
| 2021 | $36.3 | $16.1 | -56% |
| 2022 | $16.1 | $6.70 | -58% |
| 2023 | $6.70 | $5.10 | -24% |
| 2024 | $5.10 | $24.6 | +382% |
| 2025 | $24.6 | $13.9 | -43% |
| 2026 YTD | $13.9 | $1.59 | -89% |
CANG's yearly returns have swung widely, from +382% in 2024 to −58% in 2022. It's down 89% so far in 2026.